The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 10000 participants.

Also called NCT06383390

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 10,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06383390
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Romania, Slovakia, Spain, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06383390. Randomized; double masking; primary purpose treatment. Start 2024-04-30 (actual); primary completion 2029-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Condition
Atherosclerotic Cardiovascular Disease (ASCVD)
Intervention (Drug)
Retatrutide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct06383390
Content hash
cc64c1ff81156cb3914dd064ee0556d168ff47b63b4505814cbfbe08d2ae7f20